The Motley Fool··Prosper Junior BakinyPfizer's Boring Appeal: Why Blue-Chip Stability Beats Biotech Hype
Pfizer's reasonable valuation, robust pipeline, and 6.4% dividend yield offer disciplined returns versus speculative biotech like Regencell, whose 21,000% surge lacks fundamental justification.
PFERGCstock valuationclinical trials